.Pharmacolibrary.Drugs.ATC.J.J05AB16 .Pharmacolibrary.Drugs.ATC.J.J05AB16| name: | Remdesivir |
| ATC code: | J05AB16 | route: | intravenous |
| n-compartments | 2 |
Remdesivir is a broad-spectrum antiviral medication that inhibits viral RNA-dependent RNA polymerase. It was originally developed for the treatment of Ebola virus, but is more widely used today for the treatment of COVID-19 in hospitalized patients. Remdesivir is approved or authorized in many countries as a treatment for COVID-19.
Pharmacokinetic parameters in healthy adult subjects following single intravenous dose administration.
Walimbwa, SI, et al., & Lamorde, M (2021). An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). Trials 22(1) 831–None. DOI:10.1186/s13063-021-05752-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34814933
Ahmed, A, et al., & Rojo, P (2024). Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study. Pediatrics 153(3) –. DOI:10.1542/peds.2023-063775 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38332740
Coggins, SJ, et al., & Kimble, B (2025). Pharmacokinetics of GS-441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021-2024). The Journal of small animal practice None –. DOI:10.1111/jsap.13849 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40097914